JP4735069B2 - 超低比重リポ蛋白コレステロール値による薬物治療効果の判定方法 - Google Patents
超低比重リポ蛋白コレステロール値による薬物治療効果の判定方法 Download PDFInfo
- Publication number
- JP4735069B2 JP4735069B2 JP2005176598A JP2005176598A JP4735069B2 JP 4735069 B2 JP4735069 B2 JP 4735069B2 JP 2005176598 A JP2005176598 A JP 2005176598A JP 2005176598 A JP2005176598 A JP 2005176598A JP 4735069 B2 JP4735069 B2 JP 4735069B2
- Authority
- JP
- Japan
- Prior art keywords
- cholesterol
- vldl
- drug
- low density
- density lipoprotein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims description 154
- 229940079593 drug Drugs 0.000 title claims description 53
- 239000003814 drug Substances 0.000 title claims description 53
- 238000011282 treatment Methods 0.000 title claims description 50
- 230000000694 effects Effects 0.000 title claims description 26
- 238000000034 method Methods 0.000 title claims description 23
- 108010004103 Chylomicrons Proteins 0.000 title claims description 14
- 108010062497 VLDL Lipoproteins Proteins 0.000 claims description 49
- 210000004369 blood Anatomy 0.000 claims description 22
- 239000008280 blood Substances 0.000 claims description 22
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 12
- 230000007423 decrease Effects 0.000 claims description 6
- 238000004255 ion exchange chromatography Methods 0.000 claims description 5
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 4
- 239000003613 bile acid Substances 0.000 claims description 4
- 230000029142 excretion Effects 0.000 claims description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 description 64
- 108010010234 HDL Lipoproteins Proteins 0.000 description 16
- 102000015779 HDL Lipoproteins Human genes 0.000 description 16
- 108010007622 LDL Lipoproteins Proteins 0.000 description 12
- 102000007330 LDL Lipoproteins Human genes 0.000 description 12
- 102000004895 Lipoproteins Human genes 0.000 description 12
- 108090001030 Lipoproteins Proteins 0.000 description 12
- 238000005259 measurement Methods 0.000 description 11
- 230000007935 neutral effect Effects 0.000 description 11
- 238000008214 LDL Cholesterol Methods 0.000 description 5
- 108010069201 VLDL Cholesterol Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229940125753 fibrate Drugs 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 238000005199 ultracentrifugation Methods 0.000 description 4
- 108010046315 IDL Lipoproteins Proteins 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 235000019626 lipase activity Nutrition 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- -1 IDL Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Description
高脂血症患者6名について、その薬物治療経過の前後において、空腹時採血を行い、血清を得て、総コレステロール、中性脂肪、イオン交換クロマトグラフィーを用い、HDL、LDL、IDL、VLDL、カイロマイクロン中のコレステロールを測定した。これら患者は、本検討の実施期間以前から、種々の治療を受けている患者である。なお、総コレステロールと中性脂肪の測定は、和光純薬製のコレステロールEテストワコー、トリグリセライドEテストワコーにより行った。その他は、非特許文献7の方法を用いた。各患者の治療に用いた薬物の名称および薬効などを表1に、投与薬物の種類と量、治療期間、治療の前後における測定値を表2および表3に示した。表3の投薬名および経過期間は表2に準じたものである。さらに表2および表3の結果を統計処理したデータを表4に示した。
2名の患者について、複数時期において経過観察を行った。1名は高脂血症治療薬としてメバロチンを1日投与量10mgとして5月から継続投与した患者であり、5月の継続投与前と、継続投与中の7月、9月の3点において、採血を行い脂質データの変動を確認した(患者7)。1名は同じメバロチンを1日投与量20mgとして、5月から継続投与した患者であり、5月の継続投与前と、6月、7月、8月の4点において、採血を行い脂質データの変動を確認した(患者8)。脂質データの測定は、実施例1と同じとした。
Claims (5)
- 血液中の、カイロマイクロンを含まない超低比重リポ蛋白に含まれるコレステロール値をイオン交換クロマトグラフィーを用いて測定することからなる、薬物治療効果の判定方法であって、
前記超低比重リポ蛋白(VLDL)がVLDL1とVLDL2とを分けないトータルとしてのVLDLである、前記方法。 - 同一人の異なる時期に採取した血液中の、カイロマイクロンを含まない超低比重リポ蛋白に含まれるコレステロール値をイオン交換クロマトグラフィーを用いて測定し、その変動を見ることによる、薬物治療効果の判定方法であって、
前記超低比重リポ蛋白(VLDL)がVLDL1とVLDL2とを分けないトータルとしてのVLDLである、前記方法。 - 請求項1または2の血液が高脂血症患者から採取されたものである、薬物治療効果の判定方法。
- カイロマイクロンを含まない超低比重リポ蛋白に含まれるコレステロール値が低下することで高脂血症治療薬が有効であると判定することを特徴とする、請求項3の薬物治療効果の判定方法。
- 請求項1乃至4のいずれかの薬物が、HMG−CoA還元酵素阻害剤、胆汁酸排泄促進剤から選択される1以上の薬物である、薬物治療効果の判定方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005176598A JP4735069B2 (ja) | 2005-06-16 | 2005-06-16 | 超低比重リポ蛋白コレステロール値による薬物治療効果の判定方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005176598A JP4735069B2 (ja) | 2005-06-16 | 2005-06-16 | 超低比重リポ蛋白コレステロール値による薬物治療効果の判定方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006349524A JP2006349524A (ja) | 2006-12-28 |
JP4735069B2 true JP4735069B2 (ja) | 2011-07-27 |
Family
ID=37645539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005176598A Expired - Fee Related JP4735069B2 (ja) | 2005-06-16 | 2005-06-16 | 超低比重リポ蛋白コレステロール値による薬物治療効果の判定方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4735069B2 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001094619A1 (fr) * | 2000-06-07 | 2001-12-13 | International Reagents Corporation | Methode d'analyse de composants dans des echantillons biologiques |
JP2002139501A (ja) * | 2000-10-30 | 2002-05-17 | Mass Medical Kk | リポ蛋白サブクラスの分析ならびに診断方法 |
JP2005095162A (ja) * | 2003-08-20 | 2005-04-14 | Hiroyoshi Arai | スクアレンエポキシダーゼ促進因子ノックアウト動物 |
-
2005
- 2005-06-16 JP JP2005176598A patent/JP4735069B2/ja not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001094619A1 (fr) * | 2000-06-07 | 2001-12-13 | International Reagents Corporation | Methode d'analyse de composants dans des echantillons biologiques |
JP2002139501A (ja) * | 2000-10-30 | 2002-05-17 | Mass Medical Kk | リポ蛋白サブクラスの分析ならびに診断方法 |
JP2005095162A (ja) * | 2003-08-20 | 2005-04-14 | Hiroyoshi Arai | スクアレンエポキシダーゼ促進因子ノックアウト動物 |
Also Published As
Publication number | Publication date |
---|---|
JP2006349524A (ja) | 2006-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein (a) multi-ethnic study of atherosclerosis | |
Tremblay et al. | Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with β-quantification in a large population | |
Martin et al. | Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications | |
Saleh et al. | Parathyroid hormone and left ventricular hypertrophy | |
Frost et al. | Rationale for use of non–high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy | |
Kofoed et al. | Fibrinogen predicts ischaemic stroke and advanced atherosclerosis but not echolucent, rupture-prone carotid plaques: the Copenhagen City Heart Study | |
Tamada et al. | Low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a useful marker for early-stage carotid atherosclerosis | |
Lindsey et al. | A Clinical Comparison of Calculated versus Direct Measurement of Low‐Density Lipoprotein Cholesterol Level | |
Tonstad et al. | Carotid intima–media thickness and plaque in patients with familial hypercholesterolaemia mutations and control subjects | |
Gylling et al. | Physiologic mechanisms for reduced apolipoprotein AI concentrations associated with low levels of high density lipoprotein cholesterol in patients with normal plasma lipids. | |
Winocour et al. | Abnormalities of VLDL, IDL, and LDL characterize insulin-dependent diabetes mellitus. | |
US20180306822A1 (en) | Methods for determining ldl cholesterol treatment | |
JP6757870B1 (ja) | 間質性膀胱炎の診断方法 | |
Barkas et al. | High triglyceride levels alter the correlation of apolipoprotein B with low-and non-high-density lipoprotein cholesterol mostly in individuals with diabetes or metabolic syndrome | |
Bioletto et al. | Acute hyperinsulinemia and very-low-density and low-density lipoprotein subfractions in obese subjects | |
Rodríguez-Ortiz et al. | Fibroblast growth factor 23 predicts carotid atherosclerosis in individuals without kidney disease. The CORDIOPREV study | |
Carmena et al. | Coexisting dysbetalipoproteinemia and familial hypercholesterolemia: clinical and laboratory observations | |
Solnica et al. | Concordance/discordance between serum apolipoprotein B, low density lipoprotein cholesterol and non-high density lipoprotein cholesterol in NATPOL 2011 participants–an epidemiological perspective | |
Orringer | Non-HDL cholesterol, ApoB and LDL particle concentration in coronary heart disease risk prediction and treatment | |
Janac et al. | Increased oxidized high-density lipoprotein/high-density lipoprotein–cholesterol ratio as a potential indicator of disturbed metabolic health in overweight and obese individuals | |
Schmidt et al. | High apoB/apoA-I ratio is associated with increased progression rate of carotid artery intima-media thickness in clinically healthy 58-year-old men: experiences from very long-term follow-up in the AIR study | |
Gerber et al. | Indices related to apo CII and CIII serum concentrations and coronary heart disease: a case–control study | |
RU2462718C1 (ru) | Способ оценки эффективности лечения липидемии | |
JP7049137B2 (ja) | ApoE-containingHDL値を用いた冠動脈心疾患発症リスクの評価方法 | |
JP4735069B2 (ja) | 超低比重リポ蛋白コレステロール値による薬物治療効果の判定方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080514 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100715 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100727 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100915 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100915 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110111 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110329 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110411 |
|
R151 | Written notification of patent or utility model registration |
Ref document number: 4735069 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140513 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |